



November 2, 2017

✓ **BSE Limited,**  
Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**The National Stock Exchange of India Ltd.,**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI**  
**(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a press release as regards launch of Doxycycline Hyclate Tablets USP, 75 mg and 150 mg, (AB rated generic equivalent of Aqua Pharmaceuticals, LLC's Acticlate® Tablets, 75 mg and 150 mg) for which, USFDA approval was received.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully,  
For **LUPIN LIMITED**

For **R. V. SATAM**  
**COMPANY SECRETARY**

Encl.: a.a.

## Lupin launches generic Acticlate® Tablets in the US

**Mumbai, Baltimore, November 02, 2017:** Pharma Major Lupin announced the launch of its Doxycycline Hyclate Tablets USP, 75 mg and 150 mg having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Doxycycline Hyclate Tablets USP, 75 mg and 150 mg are the AB rated generic equivalent of Aqua Pharmaceuticals, LLC's Acticlate® Tablets, 75 mg and 150 mg. They are indicated in the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne.

Doxycycline Hyclate Tablets USP, 75 mg and 150 mg had annual sales of approximately USD 263 million in the US (IMS MAT June 2017).

### About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8<sup>th</sup> and 6<sup>th</sup> largest generics pharmaceutical company by market capitalization (September 30<sup>th</sup>, 2017, Bloomberg) and revenues (March 31<sup>st</sup>, 2017, Bloomberg) respectively. The Company is the 4<sup>th</sup> largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); 2<sup>nd</sup> largest Indian pharmaceutical company by global revenues (March 31<sup>st</sup>, 2017, Bloomberg); 6<sup>th</sup> largest generic pharmaceutical player in Japan and 6<sup>th</sup> largest company in Indian Pharmaceutical Market (Quintiles IMS MAT June 2017).

For the financial year ended 31<sup>st</sup> March, 2017, Lupin's Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit <http://www.lupin.com> for more information. You could also follow us on Twitter - [www.twitter.com/lupinlimited](http://www.twitter.com/lupinlimited)

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3<sup>rd</sup> Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

### For further information or queries please contact –

Pooja Thakran

VP – Corporate Communications

Email: [poojathakran@lupin.com](mailto:poojathakran@lupin.com)

Ph: +91-22-66402531 / 8291013225

Arvind Bothra

Head – Investor Relations and M&A

Email: [arvindbothra@lupin.com](mailto:arvindbothra@lupin.com)

Ph: +91-22-66402137

*\*Safe Harbor Statement*

*Acticlate® is a registered trademark of Aqua Pharmaceuticals, LLC.*